Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF for Glioblastoma
Phase-Based Progress Estimates
Effectiveness
Safety
GlioblastomaAutologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF - Biological
Study Summary
This trial is looking at whether it's possible to generate an investigational vaccine for patients with brain cancer who have already started chemotherapy.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: Leukapheresis to investigational product release date or up to 6 weeks
Week 6
Ability to generate CMV pp65 RNA-pulsed DCs in patients receiving adjuvant temozolomide chemotherapy after radiotherapy.
Trial Safety
Trial Design
1 Treatment Group
Autologous DCs derived from PBMC loaded with RNA
1 of 1
Experimental Treatment
10 Total Participants · 1 Treatment Group
Primary Treatment: Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF · No Placebo Group · Phase 1
Autologous DCs derived from PBMC loaded with RNA
Biological
Experimental Group · 1 Intervention: Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF · Intervention Types: BiologicalTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: leukapheresis to investigational product release date or up to 6 weeks
Who is running the clinical trial?
Immunomic Therapeutics, Inc.Industry Sponsor
8 Previous Clinical Trials
472 Total Patients Enrolled
2 Trials studying Glioblastoma
185 Patients Enrolled for Glioblastoma
University of FloridaLead Sponsor
1,251 Previous Clinical Trials
698,803 Total Patients Enrolled
10 Trials studying Glioblastoma
468 Patients Enrolled for Glioblastoma
Ashley Ghiaseddin, MDPrincipal InvestigatorUniversity of Florida
2 Previous Clinical Trials
49 Total Patients Enrolled
2 Trials studying Glioblastoma
49 Patients Enrolled for Glioblastoma
Eligibility Criteria
Age 18 - 90 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments